Cell regulatory and immunorestorative activity of picibanil (OK432).

M. A. Chirigos, T. Saito, J. E. Talmadge, W. Budzynski, E. Gruys

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Picibanil (OK432), a pharmaceutical preparation of a low virulent Su strain of Streptococcus pyogenes, possesses cell regulatory activity particularly in its ability to augment natural killer (NK) cell activity and to activate macrophages to exert a tumoricidal effect both in vitro and in vivo. It is effective in retarding and/or inhibiting the growth of three different tumors: MBL-2 lymphoma, M109 alveolar adenocarcinoma, and B16 melanoma. The antitumor effect is mediated through regulation of NK cells and macrophages, possibly by its ability to stimulate the production and secretion of interferon and interleukin 1 and 2. It is a very effective adjuvant for tumor cell vaccines that elicit cytotoxic T-cell responses. Following cytoreductive chemotherapy (Cytoxan) Picibanil treatment leads to an earlier reconstitution of both bone marrow cellularity and differentiation to granulocyte-macrophage colonies.

Original languageEnglish (US)
Pages (from-to)317-328
Number of pages12
JournalCancer detection and prevention. Supplement : official publication of the International Society for Preventive Oncology, Inc
Volume1
StatePublished - 1987

Fingerprint

Picibanil
Macrophages
Natural Killer Cells
Bronchiolo-Alveolar Adenocarcinoma
Experimental Melanomas
Cancer Vaccines
Streptococcus pyogenes
Interleukin-1
Granulocytes
Cyclophosphamide
Interferons
Interleukin-2
Lymphoma
Bone Marrow
T-Lymphocytes
Drug Therapy
Growth
Pharmaceutical Preparations
Neoplasms
Therapeutics

Cite this

@article{e4469053b46b4ae69c8adbeeb5d14a67,
title = "Cell regulatory and immunorestorative activity of picibanil (OK432).",
abstract = "Picibanil (OK432), a pharmaceutical preparation of a low virulent Su strain of Streptococcus pyogenes, possesses cell regulatory activity particularly in its ability to augment natural killer (NK) cell activity and to activate macrophages to exert a tumoricidal effect both in vitro and in vivo. It is effective in retarding and/or inhibiting the growth of three different tumors: MBL-2 lymphoma, M109 alveolar adenocarcinoma, and B16 melanoma. The antitumor effect is mediated through regulation of NK cells and macrophages, possibly by its ability to stimulate the production and secretion of interferon and interleukin 1 and 2. It is a very effective adjuvant for tumor cell vaccines that elicit cytotoxic T-cell responses. Following cytoreductive chemotherapy (Cytoxan) Picibanil treatment leads to an earlier reconstitution of both bone marrow cellularity and differentiation to granulocyte-macrophage colonies.",
author = "Chirigos, {M. A.} and T. Saito and Talmadge, {J. E.} and W. Budzynski and E. Gruys",
year = "1987",
language = "English (US)",
volume = "1",
pages = "317--328",
journal = "Cancer detection and prevention. Supplement : official publication of the International Society for Preventive Oncology, Inc",
issn = "1043-6995",

}

TY - JOUR

T1 - Cell regulatory and immunorestorative activity of picibanil (OK432).

AU - Chirigos, M. A.

AU - Saito, T.

AU - Talmadge, J. E.

AU - Budzynski, W.

AU - Gruys, E.

PY - 1987

Y1 - 1987

N2 - Picibanil (OK432), a pharmaceutical preparation of a low virulent Su strain of Streptococcus pyogenes, possesses cell regulatory activity particularly in its ability to augment natural killer (NK) cell activity and to activate macrophages to exert a tumoricidal effect both in vitro and in vivo. It is effective in retarding and/or inhibiting the growth of three different tumors: MBL-2 lymphoma, M109 alveolar adenocarcinoma, and B16 melanoma. The antitumor effect is mediated through regulation of NK cells and macrophages, possibly by its ability to stimulate the production and secretion of interferon and interleukin 1 and 2. It is a very effective adjuvant for tumor cell vaccines that elicit cytotoxic T-cell responses. Following cytoreductive chemotherapy (Cytoxan) Picibanil treatment leads to an earlier reconstitution of both bone marrow cellularity and differentiation to granulocyte-macrophage colonies.

AB - Picibanil (OK432), a pharmaceutical preparation of a low virulent Su strain of Streptococcus pyogenes, possesses cell regulatory activity particularly in its ability to augment natural killer (NK) cell activity and to activate macrophages to exert a tumoricidal effect both in vitro and in vivo. It is effective in retarding and/or inhibiting the growth of three different tumors: MBL-2 lymphoma, M109 alveolar adenocarcinoma, and B16 melanoma. The antitumor effect is mediated through regulation of NK cells and macrophages, possibly by its ability to stimulate the production and secretion of interferon and interleukin 1 and 2. It is a very effective adjuvant for tumor cell vaccines that elicit cytotoxic T-cell responses. Following cytoreductive chemotherapy (Cytoxan) Picibanil treatment leads to an earlier reconstitution of both bone marrow cellularity and differentiation to granulocyte-macrophage colonies.

UR - http://www.scopus.com/inward/record.url?scp=0023515287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023515287&partnerID=8YFLogxK

M3 - Article

C2 - 3480058

AN - SCOPUS:0023515287

VL - 1

SP - 317

EP - 328

JO - Cancer detection and prevention. Supplement : official publication of the International Society for Preventive Oncology, Inc

JF - Cancer detection and prevention. Supplement : official publication of the International Society for Preventive Oncology, Inc

SN - 1043-6995

ER -